AlphAIalphai — Financial news for AI agents
SEC EDGARAUG 241 min read$KURA

Powl Brian T. sold $52K of KURA

Powl Brian T. (Chief Commercial Officer) sold 4,345 shares of Kura Oncology, Inc. (KURA) at $11.89 on 2026-08-21 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · Powl Brian T.
Published Aug 24, 2026, 9:30 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Aug 24, 2026, 9:44 PM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About alphai AI DeskScoring methodologyReport an issue
alphai market briefInsider activity
Primary signal
$KURA
Neutral
high confidence
Mentioned
$KURA
Relevance
2/10
alphai data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$KURANeutralLow
01

Why it matters

The transaction reflects a routine liquidity event for the executive and does not alter company fundamentals.

02

Market read

Limited relevance; typical for small insider sales.

03

What to watch

Potential upcoming clinical milestones could change relevance of insider activity.

Relevance 2/10Novelty 4/10Timing: filed today

Background

Form 4 filing discloses insider transactions required by SEC regulations.

Company-level read

Ticker impact

$KURANeutralHigh confidence
Context

Chief Commercial Officer sold 4,345 shares for $51.7K via a 10b5-1 plan.

Expected impact

No immediate price impact expected.

Evidence & confidence

Sale size is small relative to total shares outstanding and typical trading volume.

Market effects

Sector

No broader sector impact; insider sale is company‑specific.

Regional

None

Global

None

Counterpoint

What could challenge this read

Even small insider sales can signal confidence issues; monitor future filings.

Key entities

  • Company
    Kura Oncology, Inc.

    Biotech firm developing oncology therapies.

  • Executive
    Brian T. Powl

    Chief Commercial Officer of Kura Oncology.

Read at source← All news

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

KURA insider trading history →

Related articles

AUG 25
$KURAMed

Why is Kura Oncology stock surging today?

Kura Oncology's stock rose 11.6% in pre-market trading after CEO Troy Wilson bought 100,000 shares for $1.24 million, his second large purchase in a week. Analysts Citigroup and Jefferies reaffirmed positive ratings, citing strong commercial momentum for KOMZIFTI and Q2 earnings beat. The stock surpassed its 52-week high of $12.90.

investing.com2 min
AUG 19
$KURAHighAI 8/10

Kura Oncology (KURA) Q2 2026 Earnings Call Transcript

Kura Oncology (KURA) reported Q2 2026 earnings, with KOMZIFTI net product revenue up 57% QoQ to $9.1M. New patient starts increased 35% to 115, capturing majority market share in a specific leukemia segment. Total prescriptions rose 59% to 250. Cash decreased to $519M from $667.2M. Collaboration revenue guidance set at $45M-$55M for 2026. Net loss was $68.3M, up from $66.1M YoY. Clinical data showed strong results for ziftomenib and darlifarnib. Management expects pivotal trial results in 2028.

fool.com3 min
AUG 12
$KURAMed

Kura Oncology, Inc. (KURA): Results of Operations and Financial Condition

Kura Oncology, Inc. (KURA) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Kura Oncology Reports SECOND Quarter 2026 Financial Results – KOMZIFTI ® (ziftomenib) generated $9.1 million in net product revenue, up 57% over 1Q, and approximately 115 new patient starts, up 35% over 1Q – – KOMZIFTI ® achieved majority share of new patient starts

SEC EDGAR 8-K6 min